Article
Using plasma cell‐free DNA to monitor the chemoradiotherapy course of cervical cancer
28 Mar 2019
Abstract excerpt
The liquid biopsy is being integrated into cancer diagnostics and surveillance. However, critical questions still remain, such as how to precisely evaluate cancer mutation burden and interpret the corresponding clinical implications. Herein, we evaluated the role of peripheral blood cell-free DNA (cfDNA) in characterizing the dynamic mutation alterations of 48 cancer driver genes from cervical cancer patients. We...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.
